IL2 and type 1 diabetes mellitus: We further observed that a quarter of all patients has received prior immunotherapy, and it is possible that this influenced the results, as it was previously observed that the combination of rapamycin and IL-2 transiently decreased C-peptide levels in T1D patients (73), and additionally T1D was also a reported side effect of interferon therapy (74).